Menu

Looking for Loners

A new algorithm opens doors for detecting rare cell types in mRNA sequencing.

Dec 1, 2015
Karen Zusi

ODDBALLS: Intestinal epithelium from a mouse with a single rare enteroendocrine cell positive for the Reg4 marker (bright pink)ANNA LYUBIMOVA

EDITOR'S CHOICE IN CELL & MOLECULAR BIOLOGY

The paper
D. Grün et al., “Single-cell messenger RNA sequencing reveals rare intestinal cell types,” Nature, 525:251-55, 2015.

Individuality
The advent of mRNA sequencing for individual cells has given scientists unprecedented insight into the diversity of cell populations once thought to be uniform. But finding an analysis sensitive enough to pick up rare cell types within a tissue is a challenge, says Dominic Grün, a quantitative biologist now at the Max Planck Institute of Immunobiology
and Epigenetics in Germany.

An intestinal model
To develop a technique that could pinpoint uncommon cells, Grün started with sequencing the cells in intestinal organoids and creating clusters of similar transcriptome profiles. Knowing how much gene-expression variability he could expect in a group of homogeneous cells, Grün picked out clusters of cells whose expression profiles exceeded this threshold. “The trick was to quantitate that,” he says. “I wanted to develop an algorithm that would find these rare cells without any information—without relying on previously known marker genes.”

Searching for cells
Grün’s algorithm detected enteroendocrine cells, rare, hormone-producing intestinal cells marked by high expression of the Reg4 gene. But the team delved deeper, enriching a new set of organoids for these rare cells and mining for previously unknown enteroendocrine subtypes. The tool was sensitive enough to pick up cell types represented by only a single cell.

Development
“Most universities don’t have the computational infrastructure to analyze data sets like this,” says Chris Lengner, a cell biologist at the University of Pennsylvania who did not participate in the study. “If they can make this tool readily available and user-friendly, it would probably have a pretty big impact.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.